冠心病合并2型糖尿病患者血清MMP-9, TIMP-1及hs-CRP水平的检测及其临床意义

Objective: To explore the effect of matrix metalloproteinase-9 (MMP-9), tissue inhibitor of metalloproteinase-1 (TIMP-1) and high sensitive C-reactive protein (hs-CRP) in coronary heart disease (CHD) with type 2 diabetes mellitus (T2DM). Methods: Thirty one CHD with T2DM and 50 patiens with CHD were chosen; and 30 healthy volunteers served as control group. MMP-9 and TIMP-1 in serum were measured with ELISA, hs-CRP in serum was measured by immunoturbidimetric method. Results: The level of MMP-9 in CHD with T2DM (M=409.62ng/mL) was significantly higher than that of CHD group (M=263.40ng/mL) (P＜0.05) and the control group [(196.15±44.89) ng/mL](P＜0.05). The level of TIMP-1 in CHD with T2DM [(229.27±46.85) ng/mL] was significantly lower than that of control group [(272.75±72.35) ng/mL] (P＜0.05). The level of hs-CRP in CHD with T2DM (M=17.20mg/L) was significantly higher than that of CHD group (M=4.57mg/L) (P＜0.01) and that of the control group [(1.52±0.78) mg/ L] (P＜0.01). MMP-9 and TIMP-1 were significantly related with hs-CRP in CHD with T2DM [(r=0.482, P＜0.01) (r=0.458, P＜0.05)]. Conclusion: Combined detection of serum MMP-9, TIMP-1 and hs-CRP can be used as effective clinical parameters forecasting diabetes related coronary atherosclerosis.